口服分支链氨基酸是治疗肝脏脑病的经济有效选择
Hankil Lee1, Sang Hoon Ahn2,3,4, Beom Kyung Kim2,3,5
1College of Pharmacy, Ewha Womans University, Seoul, Korea.
Yonsei medical journal
|October 27, 2025
概括
口服分支链氨基酸 (BCAA) 补充剂是预防肝硬化患者肝脏脑病 (HE) 复发的成本效益高. 这种疗法改善了患者的治疗结果,并为医疗保健系统提供了经济效益.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床营养学 临床营养学
- 卫生经济学 卫生经济学
背景情况:
- 肝硬化患者,特别是肝脑病 (HE) 患者,可以从口服分支链氨基酸 (BCAA) 补充中受益.
- 评估BCAA的成本效益对于优化HE管理至关重要.
研究的目的:
- 评估口服BCAA补充剂在改善肝脏脑病变 (HE) 患者预后方面的成本效益.
主要方法:
- 一个为期5年的马尔科夫模型比较了10,000名虚拟HE患者的BCAA治疗与不补充治疗的成本和有效性.
- 关键指标包括高等教育复发,死亡,寿命,质量调整寿命 (QALYs) 和增量成本效益比 (ICER).
- 进行了敏感性分析,以评估研究结果的可靠性.
主要成果:
- BCAA治疗减少了34%的HE复发和18%的HE相关死亡.
- 在BCAA组中,平均成本较高 (27,088美元对23,003美元),但在5年内获得0.34个QALY (2.77对2.43).
- ICER为12,017美元/QALY,显示出高成本效益,在人均GDP1的支付意愿门下,成本效益的概率为80%.
结论:
- 口服BCAA代表了在肝硬化中预防HE的成本有效策略.
- 这种治疗方法对患者的临床状况和国家医疗保健预算都有积极的影响.
相关概念视频
Amino Acid Biosynthetic Pathways
1.1K
Amino acid biosynthesis is essential for cell growth, protein synthesis, and metabolic regulation. Cells generate essential and non-essential amino acids from metabolic intermediates to sustain vital biological functions. These intermediates originate from key metabolic pathways: glycolysis, the tricarboxylic acid (TCA) cycle, and the pentose phosphate pathway. Important precursors include α-ketoglutarate, pyruvate, oxaloacetate, phosphoenolpyruvate, and erythrose-4-phosphate, which...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
806
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
806
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.8K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210


